Proinflammatory and profibrotic mediators: Principal effectors of leiomyoma development as a fibrotic disorder

Seminars in Reproductive Medicine

Volumn 28, Issue 3, 2010, Pages 180-203

  Chegini, Nasser ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Chemokines; Cytokines; Fibrosis; Inflammation; Leiomyoma; Proteases

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; ASOPRISNIL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; MICRORNA; MIFEPRISTONE; ONAPRISTONE; RALOXIFENE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; ULIPRISNIL ACETATE; UNCLASSIFIED DRUG;

CELL SPECIFICITY; CELL TRANSFORMATION; CELL TYPE; FIBROSIS; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UTERUS MYOMA;

FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEIOMYOMA; MICRORNAS; PHENOTYPE; TRANSFORMING GROWTH FACTOR BETA; UTERINE NEOPLASMS;

EID: 77951590255     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1251476     Document Type: Review

References (264)

1. Holly J. Physiology of the IGF system. Novartis Found Symp 2004 262 19-26, 2635, 265268 (Pubitemid 41322969)
2. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000 121 (1) 1-8 (Pubitemid 30665733)
3. Ligon A H., Morton C C. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update 2001 7 (1) 8-14
4. Lobel M K., Somasundaram P, Morton C C. The genetic heterogeneity of uterine leiomyomata. Obstet Gynecol Clin North Am 2006 33 (1) 13-39 (Pubitemid 43295358)
5. Parker W H. Uterine myomas: management. Fertil Steril 2007 88 (2) 255-271
6. Parker W H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007 87 (4) 725-736
7. Wallach E E., Vlahos N F. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004 104 (2) 393-406
8. Stewart E A. Uterine fibroids. Lancet 2001 357 (9252) 293-298 (Pubitemid 32120866)
9. Bradley L D. Uterine fibroid embolization: a viable alternative to hysterectomy. Am J Obstet Gynecol 2009 201 (2) 127-135
10. Lénárd Z M., McDannold N J., Fennessy F M. et al. Uterine leiomyomas: MR imaging-guided focused ultrasound surgeryimaging predictors of success. Radiology 2008 249 (1) 187-194
11. Wada-Hiraike O, Yamamoto N, Osuga Y, Yano T, Kozuma S, Taketani Y. Aberrant implantation and growth of uterine leiomyoma in the abdominal wall after laparoscopically assisted myomectomy. Fertil Steril 2009 92 (5) 1747, e13-e15
12. DeManno D, Elger W, Garg R et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003 68 (1013) 1019-1032 (Pubitemid 37532427)
13. Eisinger S H., Meldrum S, Fiscella K, le Roux H D., Guzick D S. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003 101 (2) 243-250 (Pubitemid 36170124)
14. Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004 81 (1) 132-136 (Pubitemid 38058338)
15. Palomba S, Russo T, Orio F Jr et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 2002 17 (12) 3213-3219 (Pubitemid 35469276)
16. Palomba S, Orio F Jr, Morelli M et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002 87 (8) 3603-3608 (Pubitemid 34879502)
17. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000 73 (5) 1006-1011 (Pubitemid 30227527)
18. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel C A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007 87 (6) 1399-1412 (Pubitemid 46829155)
19. Lee B S., Nowak R A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001 86 (2) 913-920
20. Levens E D., Potlog-Nahari C, Armstrong A Y. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008 111 (5) 1129-1136 (Pubitemid 351620347)
21. Spitz I M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009 21 (4) 318-324
22. Chegini N. Implication of growth factor and cytokine networks in leiomyomas In: Hill J Cytokines in Human Reproduction. New York, NY Wiley & Sons 2000 133-159
23. Chegini N, Verala J, Luo X, Xu J, Williams R S. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig 2003 10 (3) 161-171 (Pubitemid 36434150)
24. Luo X, Ding L, Xu J, Williams R S., Chegini N. Leiomyoma and myometrial gene expression profiles and their responses to gonadotropin-releasing hormone analog therapy. Endocrinology 2005 146 (3) 1074-1096 (Pubitemid 40289298)
25. Walker C L., Stewart E A. Uterine fibroids: the elephant in the room. Science 2005 308 (5728) 1589-1592
26. Chegini N, Ma C, Tang X M., Williams R S. Effects of GnRH analogues, add-back steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002 8 (12) 1071-1078 (Pubitemid 36032844)
27. Chen W, Ohara N, Wang J et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006 91 (4) 1296-1304
28. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 2004 89 (11) 5549-5557 (Pubitemid 39518439)
29. Ohara N, Morikawa A, Chen W et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007 14 (8, suppl) 20-27
30. Ohara N. Action of progesterone receptor modulators on uterine leiomyomas. Clin Exp Obstet Gynecol 2008 35 (3) 165-166
31. Stewart E A., Austin D J., Jain P, Penglase M D., Nowak R A. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium. Fertil Steril 1996 65 (6) 1119-1124 (Pubitemid 26158626)
32. Williams A R., Critchley H O., Osei J et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007 22 (6) 1696-1704 (Pubitemid 47061342)
33. Xu Q, Takekida S, Ohara N et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005 90 (2) 953-961 (Pubitemid 40279221)
34. Xu Q, Ohara N, Chen W et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006 21 (9) 2408-2416 (Pubitemid 44530620)
35. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008 14 (3) 181-191 (Pubitemid 351404891)
36. Madauss K P., Grygielko E T., Deng S J. et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007 21 (5) 1066-1081 (Pubitemid 46984759)
37. Hussein-Fikret S, Fuller P J., Gargett C E. Expression of steroid receptor coactivators in cultured cells from paired myometrial and fibroid tissues. J Soc Gynecol Investig 2005 12 (6) 445-451 (Pubitemid 41242385)
38. Berman J M. Intrauterine adhesions. Semin Reprod Med 2008 26 (4) 349-355
39. Davies C, Gibson M, Holt E M., Torrie E P. Amenorrhoea secondary to endometrial ablation and Asherman's syndrome following uterine artery embolization. Clin Radiol 2002 57 (4) 317-318 (Pubitemid 36503371)
40. Hare A A., Olah K S. Pregnancy following endometrial ablation: a review article. J Obstet Gynaecol 2005 25 (2) 108-114 (Pubitemid 43323020)
41. Magos A. Hysteroscopic treatment of Asherman's syndrome. Reprod Biomed Online 2002 4 (suppl 3) 46-51
42. Buchanan E P., Longaker M T., Lorenz H P. Fetal skin wound healing. Adv Clin Chem 2009 48 137-161
43. Kalluri R, Weinberg R A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009 119 (6) 1420-1428
44. Kisseleva T, Brenner D A. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006 21 (suppl 3) S84-S87 (Pubitemid 44266558)
45. Kisseleva T, Uchinami H, Feirt N et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006 45 (3) 429-438 (Pubitemid 44142115)
46. Kisseleva T, Brenner D A. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008 233 (2) 109-122 (Pubitemid 351231543)
47. Lee E Y., Xia Y, Kim W S. et al. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen 2009 17 (4) 540-547
48. Martínez-Climent J A., Andreu E J., Prosper F. Somatic stem cells and the origin of cancer. Clin Transl Oncol 2006 8 (9) 647-663
49. Mehrad B, Burdick M D., Zisman D A., Keane M P., Belperio J A., Strieter R M. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007 353 (1) 104-108 (Pubitemid 44958347)
50. Stappenbeck T S., Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science 2009 324 (5935) 1666-1669
51. Mattoli S, Bellini A, Schmidt M. The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implications for therapy. Curr Stem Cell Res Ther 2009 December 1 (Epub ahead of print)
52. Chen Y, Xiang L X., Shao J Z., Pan R L., Wang Y X., Dong XJ, et al. Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver. J Cell Mol Med 2009 September 24 (Epub ahead of print)
53. Keeley E C., Mehrad B, Strieter R M. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb Haemost 2009 101 (4) 613-618
54. Chang H L., Senaratne T N., Zhang L et al. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci 2009 October 5 (Epub ahead of print)
55. Ono M, Maruyama T, Masuda H et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A 2007 104 (47) 18700-18705 (Pubitemid 350210760)
56. Acloque H, Thiery J P., Nieto M A. The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep 2008 9 (4) 322-326
57. Acloque H, Adams M S., Fishwick K, Bronner-Fraser M, Nieto M A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009 119 (6) 1438-1449
58. Singer A J., Clark R A. Cutaneous wound healing. N Engl J Med 1999 341 (10) 738-746
59. Fitzpatrick F A., Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001 107 (11) 1347-1351 (Pubitemid 32522026)
60. Fitzpatrick F A. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 2004 10 (6) 577-588
61. Bennett J S. Platelet-fibrinogen interactions. Ann N Y Acad Sci 2001 936 340-354
62. Bennett J S., Berger B W., Billings P C. The structure and function of platelet integrins. J Thromb Haemost 2009 7 (suppl 1) 200-205
63. Clemetson K J., Clemetson J M. Platelet receptor signalling. Hematol J 2004 5 (suppl 3) S159-S163
64. Clemetson K J., Clemetson J M. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007 13 (26) 2673-2683
65. Hinz B, Phan S H., Thannickal V J., Galli A, Bochaton-Piallat M L., Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007 170 (6) 1807-1816 (Pubitemid 47339255)
66. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007 127 (3) 526-537 (Pubitemid 46271018)
67. Clark R A. Fibrin and wound healing. Ann N Y Acad Sci 2001 936 355-367
68. Hwu Y M., Li S H., Lee R K., Tsai Y H., Yeh T S., Lin S Y. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril 2008 89 (2) 468-471
69. Miura S, Khan K N., Kitajima M et al. Differential infiltration of macrophages and prostaglandin production by different uterine leiomyomas. Hum Reprod 2006 21 (10) 2545-2554 (Pubitemid 44542145)
70. Sozen I, Olive D L., Arici A. Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata. Fertil Steril 1998 69 (6) 1095-1102 (Pubitemid 28274900)
71. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin North Am 2006 33 (1) 41-58 (Pubitemid 43295359)
72. Suzuki M, Takamizawa S, Nomaguchi K et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001 113 (1) 49-51 (Pubitemid 32423301)
73. Mesquita F S., Dyer S N., Heinrich D A., Bulun S E., Marsh E E., Nowak R A. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod 2010 82 (2) 341-351
74. Collen D, Lijnen H R. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009 29 (8) 1151-1155
75. Holly S P., Larson M K., Parise L V. Multiple roles of integrins in cell motility. Exp Cell Res 2000 261 (1) 69-74
76. Lijnen H R. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001 936 226-236
77. Lijnen H R. Extracellular proteolysis in the development and progression of atherosclerosis. Biochem Soc Trans 2002 30 (2) 163-167
78. Lijnen H R. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002 67 (1) 92-98
79. Andreou A, Feussner I. Lipoxygenasesstructure and reaction mechanism. Phytochemistry 2009 70 (1314) 1504-1510
80. Chawengsub Y, Gauthier K M., Campbell W B. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 2009 297 (2) H495-H507
81. Mochizuki N, Kwon Y G. 15-lipoxygenase-1 in the vasculature: expanding roles in angiogenesis. Circ Res 2008 102 (2) 143-145 (Pubitemid 351651114)
82. O'Donnell V B., Maskrey B, Taylor G W. Eicosanoids: generation and detection in mammalian cells. Methods Mol Biol 2009 462 5-23
83. Wymann M P., Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008 9 (2) 162-176 (Pubitemid 351158917)
84. Aitokallio-Tallberg A. Prostacyclin and thromboxane synthesis by endometrial cancer and leiomyomas. Prostaglandins 1990 39 (3) 259-266 (Pubitemid 20094235)
85. Pinto S, Coppo M, Bruni V, Rosati D, Cirri R, Abbate R. Changes in thromboxane A2 generation and plasma lipid pattern in pseudomenopause induced by gonadotropin releasing hormone (GnRH) analogue buserelin. Prostaglandins Leukot Essent Fatty Acids 1991 43 (3) 203-207
86. Rees M C., Turnbull A C. Leiomyomas release prostaglandins. Prostaglandins Leukot Med 1985 18 (1) 65-68
87. Yamaguchi M, Mori N. Prostaglandin production by human myometrium, uterine cervix and leiomyoma. Prostaglandins Leukot Med 1987 29 (1) 107-112 (Pubitemid 17150445)
88. O'Garra A, Robinson D. Development and function of T helper 1 cells. Adv Immunol 2004 83 133-162 (Pubitemid 38657639)
89. Stetson D B., Voehringer D, Grogan J L. et al. Th2 cells: orchestrating barrier immunity. Adv Immunol 2004 83 163-189 (Pubitemid 38657640)
90. Gerard C, Rollins B J. Chemokines and disease. Nat Immunol 2001 2 (2) 108-115 (Pubitemid 33707927)
91. Lau E K., Allen S, Hsu A R., Handel T M. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv Protein Chem 2004 68 351-391 (Pubitemid 41184485)
92. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000 12 (2) 121-127 (Pubitemid 30398626)
93. Keeley E C., Mehrad B, Strieter R M. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008 28 (11) 1928-1936
94. Mehrad B, Keane M P., Strieter R M. Chemokines as mediators of angiogenesis. Thromb Haemost 2007 97 (5) 755-762 (Pubitemid 46804315)
95. Dimitrova I K., Richer J K., Rudolph M C. et al. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril 2009 91 (6) 2650-2663
96. Wei T, Geiser A G., Qian H R. et al. DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health 2007 7 5 (Pubitemid 46614512)
97. Wei J J., Chiriboga L, Arslan A A., Melamed J, Yee H, Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 2006 21 (1) 57-67 (Pubitemid 41794292)
98. Wei J J., Chiriboga L, Mittal K. Expression profile of the tumorigenic factors associated with tumor size and sex steroid hormone status in uterine leiomyomata. Fertil Steril 2005 84 (2) 474-484 (Pubitemid 41125273)
99. Ahn W S., Kim K W., Bae S M. et al. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 2003 84 (6) 267-279
100. Wang H, Mahadevappa M, Yamamoto K et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003 80 (2) 266-276 (Pubitemid 36959779)
101. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005 146 (3) 1097-1118 (Pubitemid 40289299)
102. Luo X, Ding L, Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod 2006 12 (4) 245-256 (Pubitemid 43779076)
103. Luo X, Pan Q, Liu L, Chegini N. Genomic and proteomic profiling II: comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars. Reprod Biol Endocrinol 2007 5 35 (Pubitemid 47628988)
104. Pan Q, Luo X, Chegini N. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol 2007 5 34 (Pubitemid 350064721)
105. Wei J J., Chiriboga L, Arslan A A., Melamed J, Yee H, Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 2006 21 (1) 57-67 (Pubitemid 41794292)
106. Chegini N, Tang X M., Ma C. Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 1999 84 (11) 4138-4143 (Pubitemid 30644206)
107. Luo X, Ding L, Xu J, Williams R S., Chegini N. Leiomyoma and myometrial gene expression profiles and their responses to gonadotropin-releasing hormone analog therapy. Endocrinology 2005 146 (3) 1074-1096 (Pubitemid 40289298)
108. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004 10 (3) 207-220 (Pubitemid 38750141)
109. Chen Q, Rabach L, Noble P et al. IL-11 receptor alpha in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2005 174 (4) 2305-2313 (Pubitemid 40223979)
110. Fichtner-Feigl S, Young C A., Kitani A, Geissler E K., Schlitt H J., Strober W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008 135 (6) 2003-2013
111. Malavia N K., Mih J D., Raub C B., Dinh B T., George S C. IL-13 induces a bronchial epithelial phenotype that is profibrotic. Respir Res 2008 9 27
112. Nishimura Y, Nitto T, Inoue T, Node K. IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J 2008 72 (3) 469-475 (Pubitemid 351600645)
113. Reiman R M., Thompson R W., Feng C G. et al. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun 2006 74 (3) 1471-1479
114. Sugimoto R, Enjoji M, Nakamuta M et al. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int 2005 25 (2) 420-428 (Pubitemid 40500578)
115. Wynn T A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004 4 (8) 583-594
116. Yamagata S, Tomita K, Sato R, Niwa A, Higashino H, Tohda Y. Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model. Clin Exp Immunol 2008 154 (3) 295-304
117. Zheng T, Oh M H., Oh S Y., Schroeder J T., Glick A B., Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2009 129 (3) 742-751
118. Galkowska H, Wojewodzka U, Olszewski W L. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006 14 (5) 558-565 (Pubitemid 44470072)
119. Shephard P, Hinz B, Smola-Hess S, Meister J J., Krieg T, Smola H. Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb Haemost 2004 92 (2) 262-274 (Pubitemid 39172306)
120. Kikuchi T, Shively J D., Foley J S., Drazen J M., Tschumperlin D J. Differentiation-dependent responsiveness of bronchial epithelial cells to IL-4/13 stimulation. Am J Physiol Lung Cell Mol Physiol 2004 287 (1) L119-L126 (Pubitemid 38787658)
121. Robson M C., Dubay D A., Wang X, Franz M G. Effect of cytokine growth factors on the prevention of acute wound failure. Wound Repair Regen 2004 12 (1) 38-43 (Pubitemid 38249134)
122. Mollah Z U., Aiba S, Nakagawa S et al. Interleukin-3 in cooperation with transforming growth factor beta induces granulocyte macrophage colony stimulating factor independent differentiation of human CD34+hematopoietic progenitor cells into dendritic cells with features of Langerhans cells. J Invest Dermatol 2003 121 (6) 1397-1401 (Pubitemid 38005492)
123. Jost M M., Ninci E, Meder B et al. Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. FASEB J 2003 17 (15) 2281-2283 (Pubitemid 39561466)
124. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003 9 (1) 39-49 (Pubitemid 36131704)
125. Chen G, Grotendorst G, Eichholtz T, Khalil N. GM-CSF increases airway smooth muscle cell connective tissue expression by inducing TGF-beta receptors. Am J Physiol Lung Cell Mol Physiol 2003 284 (3) L548-L556 (Pubitemid 36231734)
126. Suzuki M, Harashima A, Okochi A et al. Transforming growth factor-beta(1) augments granulocyte-macrophage colony-stimulating factor-induced proliferation of umbilical cord blood CD34(+) cells with an associated tyrosine phosphorylation of STAT5. Exp Hematol 2002 30 (10) 1132-1138
127. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002 13 (4-5) 413-421
128. Syssoev K A., Kulagina N V., Chukhlovin A B., Morozova E B., Totolian A A. Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. Bull Exp Biol Med 2008 145 (1) 84-89
129. Senturk L M., Sozen I, Gutierrez L, Arici A. Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma. Am J Obstet Gynecol 2001 184 (4) 559-566 (Pubitemid 32234966)
130. Allen G B., Cloutier M E., Larrabee Y C., Tetenev K, Smiley S T., Bates J H. Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2009 296 (3) L277-L285
131. Smiley S T., King J A., Hancock W W. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001 167 (5) 2887-2894
132. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007 19 (6) 676-680 (Pubitemid 350236803)
133. Fujiwara K, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga M. Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)alpha in neutrophil infiltration. Lab Invest 2002 82 (1) 15-23 (Pubitemid 34072642)
134. Galligan C L., Matsuyama W, Matsukawa A et al. Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum 2004 50 (6) 1806-1814 (Pubitemid 38725093)
135. Hicks A, Monkarsh S P., Hoffman A F., Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007 16 (12) 1909-1920 (Pubitemid 351403723)
136. Hogaboam C M., Bone-Larson C L., Steinhauser M L. et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am J Pathol 2000 156 (4) 1245-1252
137. Hoshino A, Kawamura Y I., Yasuhara M et al. Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. J Immunol 2007 178 (8) 5296-5304 (Pubitemid 46595315)
138. Jakubzick C, Wen H, Matsukawa A, Keller M, Kunkel S L., Hogaboam C M. Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2004 165 (4) 1211-1221 (Pubitemid 39297727)
139. LaFleur A M., Lukacs N W., Kunkel S L., Matsukawa A. Role of CC chemokine CCL6/C10 as a monocyte chemoattractant in a murine acute peritonitis. Mediators Inflamm 2004 13 (5-6) 349-355 (Pubitemid 40018369)
140. Matsukawa A, Hogaboam C M., Lukacs N W., Lincoln P M., Strieter R M., Kunkel S L. Endogenous MCP-1 influences systemic cytokine balance in a murine model of acute septic peritonitis. Exp Mol Pathol 2000 68 (2) 77-84 (Pubitemid 30170034)
141. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004 22 (5) 460-466 (Pubitemid 39472571)
142. Call D R., Nemzek J A., Ebong S J. et al. Differential local and systemic regulation of the murine chemokines KC and MIP2. Shock 2001 15 (4) 278-284
143. Coelho A L., Schaller M A., Benjamim C F., Orlofsky A Z., Hogaboam C M., Kunkel S L. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol 2007 179 (8) 5474-5482
144. Matsukawa A, Hogaboam C M., Lukacs N W. et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000 164 (5) 2738-2744 (Pubitemid 30115507)
145. Orlofsky A, Wu Y, Prystowsky M B. Divergent regulation of the murine CC chemokine C10 by Th(1) and Th(2) cytokines. Cytokine 2000 12 (3) 220-228 (Pubitemid 30449878)
146. Steinhauser M L., Hogaboam C M., Matsukawa A, Lukacs N W., Strieter R M., Kunkel S L. Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect Immun 2000 68 (11) 6108-6114
147. Hsieh Y Y., Chang C C., Tsai F J., Lin C C., Yeh L S., Tsai C H. Tumor necrosis factor-alpha-308 promoter and p53 codon 72 gene polymorphisms in women with leiomyomas. Fertil Steril 2004 82 (suppl 3) 1177-1181
148. Hsieh Y Y., Chang C C., Tsai C H., Lin C C., Tsai F J. Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 114, IL-4-590 intron 3, IL-8 3-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma. Fertil Steril 2007 87 (4) 886-895
149. Litovkin K V., Domenyuk V P., Bubnov V V., Zaporozhan V N. Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 2007 29 (4) 295-298
150. Pietrowski D, Thewes R, Sator M, Denschlag D, Keck C, Tempfer C. Uterine leiomyoma is associated with a polymorphism in the interleukin 1-beta gene. Am J Reprod Immunol 2009 62 (2) 112-117
151. Carpenter K L., van der Veen C, Taylor S E. et al. Macrophages, lipid oxidation, ceroid accumulation and alpha-tocopherol depletion in human atherosclerotic lesions. Gerontology 1995 41 (suppl 2) 53-67
152. Cinel I, Opal S M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009 37 (1) 291-304
153. Furuichi K, Gao J L., Horuk R, Wada T, Kaneko S, Murphy P M. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol 2008 181 (12) 8670-8676
154. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009 13 (1) 9-14
155. Hardwick S J., Hegyi L, Clare K et al. Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein. J Pathol 1996 179 (3) 294-302 (Pubitemid 26266409)
156. Hodge J C., Morton C C. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet 2007 16 Spec No 1 R7-13
157. Coraux C, Roux J, Jolly T, Birembaut P. Epithelial cell-extracellular matrix interactions and stem cells in airway epithelial regeneration. Proc Am Thorac Soc 2008 5 (6) 689-694
158. Gill S E., Parks W C. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008 40 (6-7) 1334-1347
159. Moali C, Hulmes D J. Extracellular and cell surface proteases in wound healing: new players are still emerging. Eur J Dermatol 2009 19 (6) 552-564
160. Page-McCaw A, Ewald A J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007 8 (3) 221-233 (Pubitemid 46310551)
161. Ra H J., Parks W C. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007 26 (8) 587-596
162. Toriseva M, Kähäri V M. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009 66 (2) 203-224
163. Behera M A., Feng L, Yonish B, Catherino W, Jung S H., Leppert P. Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci 2007 14 (8, suppl) 63-76
164. Dou Q, Tarnuzzer R W., Williams R S., Schultz G S., Chegini N. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod 1997 3 (11) 1005-1014 (Pubitemid 127509967)
165. Ma C, Chegini N. Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-beta1. Mol Hum Reprod 1999 5 (10) 950-954 (Pubitemid 29470320)
166. Palmer S S., Haynes-Johnson D, Diehl T, Nowak R A. Increased expression of stromelysin 3 mRNA in leiomyomas (uterine fibroids) compared with myometrium. J Soc Gynecol Investig 1998 5 (4) 203-209 (Pubitemid 28359817)
167. Takemura N, Yoshida S, Kennedy S, Deguchi M, Ohara N, Maruo T. Matrix metalloproteinase-1 and -9 promoter polymorphisms are not associated with an increased risk of uterine leiomyomas in a Japanese population. J Soc Gynecol Investig 2006 13 (3) 232-236 (Pubitemid 44528299)
168. Wolaska M, Sobolewski K, Bakowski E, Jaworski S. Matrix metalloproteinases of human leiomyoma in various stages of tumor growth. Gynecol Obstet Invest 2004 58 (1) 14-18 (Pubitemid 39140401)
169. Byrne A M., Bouchier-Hayes D J., Harmey J H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005 9 (4) 777-794 (Pubitemid 43116546)
170. Hickey M M., Simon M C. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 2006 76 217-257 (Pubitemid 44773777)
171. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005 3 (4) 309-314 (Pubitemid 41264282)
172. Kopp H G., Ramos C A., Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 2006 13 (3) 175-181 (Pubitemid 43755858)
173. Murdoch C, Muthana M, Lewis C E. Hypoxia regulates macrophage functions in inflammation. J Immunol 2005 175 (10) 6257-6263 (Pubitemid 41598863)
174. Rodriguez P G., Felix F N., Woodley D T., Shim E K. The role of oxygen in wound healing: a review of the literature. Dermatol Surg 2008 34 (9) 1159-1169
175. Sen C K. Wound healing essentials: let there be oxygen. Wound Repair Regen 2009 17 (1) 1-18
176. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001 26 (1) 25-35 (Pubitemid 32421949)
177. Arnout J, Hoylaerts M F., Lijnen H R. Haemostasis. Handb Exp Pharmacol 2006 (176 Pt 2) 1-41
178. Fichtner-Feigl S, Strober W, Geissler E K., Schlitt H J. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol 2008 1 (suppl 1) S24-S27
179. Fujimoto H, Gabazza E C., Taguchi O et al. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 2006 168 (4) 1086-1096
180. Galkowska H, Wojewodzka U, Olszewski W L. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006 14 (5) 558-565 (Pubitemid 44470072)
181. Johnson L L., Berggren K N., Szaba F M., Chen W, Smiley S T. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 2003 197 (6) 801-806 (Pubitemid 36350874)
182. Wolberg A S. Thrombin generation and fibrin clot structure. Blood Rev 2007 21 (3) 131-142
183. Cross M J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001 22 (4) 201-207 (Pubitemid 32244307)
184. Lijnen H R. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003 33 (5-6) 275-281 (Pubitemid 40278695)
185. Margosio B, Rusnati M, Bonezzi K et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008 40 (4) 700-709 (Pubitemid 351288589)
186. Owen C A. Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol 2008 40 (6-7) 1246-1272
187. Petreaca M L., Yao M, Ware C, Martins-Green M M. Vascular endothelial growth factor promotes macrophage apoptosis through stimulation of tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT). Wound Repair Regen 2008 16 (5) 602-614
188. de Caestecker M, de CM. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004 15 (1) 1-11 (Pubitemid 38121286)
189. Hyytiäinen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004 41 (3) 233-264 (Pubitemid 38888060)
190. Barcellos-Hoff M H., Akhurst R J. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 2009 11 (1) 202
191. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007 35 (Pt 4) 661-664 (Pubitemid 47310335)
192. Gharaee-Kermani M, Hu B, Phan S H., Gyetko M R. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Curr Med Chem 2009 16 (11) 1400-1417
193. Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 2009 37 (Pt 4) 849-854
194. Goumans M J., van Zonneveld A J., ten Dijke P. Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc Med 2008 18 (8) 293-298
195. Leivonen S K., Kähäri V M. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007 121 (10) 2119-2124 (Pubitemid 47585589)
196. Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci 2009 14 2923-2934
197. Moustakas A, Heldin C H. The regulation of TGFbeta signal transduction. Development 2009 136 (22) 3699-3714
198. Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci 2009 14 4848-4861
199. Pohlers D, Brenmoehl J, Löffler I et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 2009 1792 (8) 746-756
200. Schnaper H W., Jandeska S, Runyan C E. et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009 14 2448-2465
201. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009 5 (4) 200-206
202. Wu M Y., Hill C S. TGF-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009 16 (3) 329-343
203. Byfield S D., Roberts A B. Lateral signaling enhances TGF-beta response complexity. Trends Cell Biol 2004 14 (3) 107-111
204. Derynck R, Zhang Y E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003 425 (6958) 577-584 (Pubitemid 37280136)
205. ten Dijke P, Hill C S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004 29 (5) 265-273
206. Siegel P M., Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003 3 (11) 807-821 (Pubitemid 37376979)
207. Cummings J, Ward T H., Ranson M, Dive C. Apoptosis pathway-targeted drugsfrom the bench to the clinic. Biochim Biophys Acta 2004 1705 (1) 53-66 (Pubitemid 39610420)
208. Hengartner M O. The biochemistry of apoptosis. Nature 2000 407 (6805) 770-776
209. Arici A, Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am J Obstet Gynecol 2003 188 (1) 76-83 (Pubitemid 36135601)
210. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 2003 209 (12) 9-16 (Pubitemid 37353078)
211. Dou Q, Zhao Y, Tarnuzzer R W. et al. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996 81 (9) 3222-3230 (Pubitemid 26296192)
212. Dou Q, Williams R S., Chegini N. Inhibition of transforming growth factor-beta 1 alters the growth, anchor-dependent cell aggregation and integrin mRNA expression in human promonocytes: implications for endometriosis and peritoneal adhesion formation. Mol Hum Reprod 1997 3 (5) 383-391 (Pubitemid 127509381)
213. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005 146 (3) 1097-1118 (Pubitemid 40289299)
214. Tang X M., Dou Q, Zhao Y, McLean F, Davis J, Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod 1997 3 (3) 233-240 (Pubitemid 127509480)
215. Xu J, Luo X, Chegini N. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 2003 88 (3) 1350-1361 (Pubitemid 36337800)
216. Blobe G C., Schiemann W P., Lodish H F. Role of transforming growth factor beta in human disease. N Engl J Med 2000 342 (18) 1350-1358
217. Hua Z, Lv Q, Ye W et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006 1 e116
218. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008 49 (2) 103-113 (Pubitemid 350298736)
219. Yu L, Border W A., Huang Y, Noble N A. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003 64 (3) 844-856
220. Barbarisi A, Petillo O, Di Lieto A et al. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 2001 186 (3) 414-424 (Pubitemid 32147725)
221. Rossi M J., Chegini N, Masterson B J. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992 130 (3) 1716-1727
222. Laping N J., Everitt J I., Frazier K S. et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007 13 (10) 3087-3099
223. Norwitz E R., Xu S, Xu J et al. Direct binding of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene. J Biol Chem 2002 277 (40) 37469-37478
224. Norwitz E R., Xu S, Jeong K H. et al. Activin A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. Endocrinology 2002 143 (3) 985-997 (Pubitemid 34164047)
225. Ahn W S., Kim K W., Bae S M. et al. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 2003 84 (6) 267-279
226. Quade B J., Wang T Y., Sornberger K, Dal Cin P, Mutter G L., Morton C C. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004 40 (2) 97-108 (Pubitemid 38579878)
227. Tsibris J C., Segars J, Coppola D et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002 78 (1) 114-121 (Pubitemid 34722680)
228. Wang H, Mahadevappa M, Yamamoto K et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003 80 (2) 266-276 (Pubitemid 36959779)
229. Weston G, Trajstman A C., Gargett C E., Manuelpillai U, Vollenhoven B J., Rogers P A. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod 2003 9 (9) 541-549 (Pubitemid 37220813)
230. Leask A, Abraham D J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006 119 (Pt 23) 4803-4810 (Pubitemid 46017793)
231. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008 20 (8) 1409-1414
232. Joseph D S., Malik M, Nurudeen S, Catherino W H. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 2009 March 26 (Epub ahead of print)
233. Tsou R, Cole J K., Nathens A B. et al. Analysis of hypertrophic and normal scar gene expression with cDNA microarrays. J Burn Care Rehabil 2000 21 (6) 541-550 (Pubitemid 32050421)
234. Leahy D J. Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. Adv Protein Chem 2004 68 1-27 (Pubitemid 41184477)
235. Leu T H., Maa M C. Functional implication of the interaction between EGF receptor and c-Src. Front Biosci 2003 8 s28-s38 (Pubitemid 38925401)
236. Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 2000 11 (4) 335-344
237. Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 2000 22 (8) 697-707 (Pubitemid 30613301)
238. Bonner J C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004 15 (4) 255-273
239. Yu J, Ustach C, Kim H R. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003 36 (1) 49-59 (Pubitemid 36836256)
240. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003 14 (2) 91-98 (Pubitemid 36389523)
241. Vegeto E, Ghisletti S, Meda C, Etteri S, Belcredito S, Maggi A. Regulation of the lipopolysaccharide signal transduction pathway by 17beta-estradiol in macrophage cells. J Steroid Biochem Mol Biol 2004 91 (12) 59-66 (Pubitemid 38903184)
242. Moro L, Reineri S, Piranda D et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 2005 105 (1) 115-121 (Pubitemid 40053072)
243. Brekken R A., Sage E H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001 19 (8) 816-827
244. Di Lieto A, De Rosa G, De Falco M et al. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Hum Pathol 2002 33 (2) 220-224 (Pubitemid 34298738)
245. Heldin C H. Development and possible clinical use of antagonists for PDGF and TGF-beta. Ups J Med Sci 2004 109 (3) 165-178
246. LeRoith D, Roberts C T. Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003 195 (2) 127-137 (Pubitemid 36588961)
247. Firth S M., Baxter R C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002 23 (6) 824-854 (Pubitemid 35454590)
248. Gentry C C., Okolo S O., Fong L F., Crow J C., Maclean A B., Perrett C W. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001 101 (6) 691-695
249. Böttcher R T., Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005 26 (1) 63-77 (Pubitemid 40209387)
250. Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004 131 (24) 6009-6021 (Pubitemid 40123916)
251. Wu X, Blanck A, Olovsson M, Möller B, Lindblom B. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment. Acta Obstet Gynecol Scand 2001 80 (6) 497-504 (Pubitemid 32521287)
252. Taylor C V., Letarte M, Lye S J. The expression of integrins and cadherins in normal human uterus and uterine leiomyomas. Am J Obstet Gynecol 1996 175 (2) 411-419 (Pubitemid 26391001)
253. Chegini N, Kornberg L. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig 2003 10 (1) 21-26 (Pubitemid 36051094)
254. Fanayan S, Firth S M., Baxter R C. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem 2002 277 (9) 7255-7261 (Pubitemid 34953118)
255. Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 (2) 281-297
256. Bi Y, Liu G, Yang R. MicroRNAs: novel regulators during the immune response. J Cell Physiol 2009 218 (3) 467-472
257. Calin G A., Pekarsky Y, Croce C M. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007 20 (3) 425-437 (Pubitemid 47260321)
258. Luo X, Chegini N. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 2008 26 (6) 500-514
259. Wang T, Zhang X, Obijuru L et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007 46 (4) 336-347 (Pubitemid 46411325)
260. Tili E, Croce C M., Michaille J J. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009 28 (5) 264-284
261. Tili E, Michaille J J., Cimino A et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007 179 (8) 5082-5089
262. Tili E, Michaille J J., Costinean S, Croce C M. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 2008 4 (10) 534-541
263. Chegini N, Zhao Y, Williams R S., Flanders K C. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 1994 135 (1) 439-449 (Pubitemid 24978260)
264. Chegini N, Ma C, Tang X M., Williams R S. Effects of GnRH analogues, add-back steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002 8 (12) 1071-1078 (Pubitemid 36032844)